Teprotumumab (1) – Tepezza®
Endocrine orbitopathy
Characteristics
| Start date | 01.03.2026 |
|---|---|
| Resolution | 20.08.2026 – active procedure |
| INN | Teprotumumab |
| Brand name | Tepezza® |
| Pharm. company | Amgen GmbH |
| G-BA Procedure ID | D-1296 |
| Therapeutic area | Eye diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions